Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the <scp>US FDA</scp> Adverse Event Reporting System

Abstract

ICI may lead to ICIs-associated MG during therapy. Analysis of FAERS data identified signals for AEs of MG with ICI regimens. Practitioners should consider the factors that may increase the likelihood of MG. The findings support a continued surveillance and risk factor identification.